Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

Annals of Surgical Oncology

Volumn 22, Issue 7, 2015, Pages 2135-2142

  Thompson, John F ^a   Agarwala, Sanjiv S ^b   Smithers, B Mark ^c   Ross, Merrick I ^d   Scoggins, Charles R ^e   Coventry, Brendon J ^f   Neuhaus, Susan J ^f   Minor, David R ^g   Singer, Jamie M ^h   Wachter, Eric A ^h  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b ST LUKE S HOSPITAL   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h Provectus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ROSE BENGAL; FLUORESCENT DYE;

ADULT; AGED; ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INJECTION SITE CELLULITIS; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; INJECTION SITE ULCER; INJECTION SITE VESICLE; INJECTION SITE WARMTH; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEDICAL PHOTOGRAPHY; METASTATIC MELANOMA; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REGIONAL PERFUSION; TREATMENT RESPONSE; CLINICAL TRIAL; INTRALESIONAL DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORESCENT DYES; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; ROSE BENGAL; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84930480545     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4169-5     Document Type: Article

References (37)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.
2. Gimbel MI, Delman KA, Zager JS. Therapy for unresectable, recurrent and in transit extremity melanoma. Cancer Control. 2008;15:225–32.
3. Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, van Geel AN, et al. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol. 2011;104:391–6.
4. Speicher PJ, Tyler DS, Mosca PJ. Management of in-transit malignant melanoma. In: Duc GHT, editor. Melanoma—from early detection to treatment. http://www.intechopen.com/books/melanoma-from-early-detection-to-treatment/management-of-in-transit-malignant-melanoma.
5. Ross MI. Intralesional therapy with PV-10 (rose bengal) for in-transit melanoma. J Surg Oncol. 2014;109:314–9.
6. Temple-Oberle CF, Byers BA, Hurdle V, Fyfe A, McKinnon JG. Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol. 2014;109:327–31.
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, melanoma, version 4.2014. http://www.nccn.org/.
8. Delprat GD, Epstein NN, Kerr WJ. A new liver function test. The elimination of rose bengal when injected into the circulation of human subjects. Arch Intern Med. 1924;34:533–41.
9. Marsh RJ, Fraunfelder FT, McGill JI. Herpetic corneal epithelial disease. Arch Ophthalmol. 1976;94:1899–902.
10. Wachter E, Dees C, Harkins J, Fisher W, Scott T. Imaging photosensitizer distribution and pharmacology using multiphoton microscopy. In: Farkas DL, Leif RC, editors. Proceedings of SPIE, Optical diagnostics of living cells V (Vol. 4622). Bellingham. 2002. p. 112–8.
11. Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 2013;8:e68561.
12. Sarnaik A, Crago G, Liu H, Kodumudi K, Weber A, McCardle T, et al. Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions. J Clin Oncol. 2014;32(Suppl 5s):9028.
13. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional rose bengal. Melanoma Res. 2008;18:405–11.
14. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143–51.
15. National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v.3.0 (CTCAE). December 12, 2003. http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
16. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
17. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13:227–36.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.
19. Illum L, Davis SS. Cellulose microspheres as a sustained release system for parenteral administration. Int J Pharma. 1982;11:323–7.
20. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest. 2003;21:821–9.
21. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol). 2001;13:458–65.
22. Rataj D, Jankowiak B, Krajewska-Kułak E, Van Damme-Ostapowicz K, Nowecki ZI, Rutkowski P, et al. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs. 2005;28:172–8.
23. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer. 2006;94:492–8.
24. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30:3012–9.
25. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
26. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.
27. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
28. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor–encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–71.
29. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006;16:521–6.
30. Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31(Suppl):LBA9008.
31. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guérin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol. 1993;19:985–90.
32. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010;116:4139–46.
33. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715–27.
34. Polak ME, Borthwick NJ, Jager MJ, Cree IA. Melanoma vaccines: the problems of local immunosuppression. Hum Immunol. 2009;70:331–9.
35. Coventry BJ, Ashdown ML. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res. 2012;4:137–49.
36. Foote MC, Burmeister BH, Thomas, Smithers BM. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res. 2010;20:48–51.
37. Wachter EA, Blair SO, Singer JM, Dees HC. Systemic anti-CTLA-4 antibody therapy in murine models of melanoma. Cancer Res. 2013;73(8 Suppl 1):4755.